Literature DB >> 11764202

Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells.

M Kohno1, Y Aikawa, Y Tsubouchi, A Hashiramoto, R Yamada, Y Kawahito, K Inoue, Y Kusaka, M Kondo, H Sano.   

Abstract

OBJECTIVE: To investigate the mechanism of the immunosuppressive effect of T-614 [N-(3-formylamino-4-oxo-6-phenoxy-4H-chromen-7-yl)methanesulfonamide], a new antirheumatic drug whose clinical efficacy has been determined for the treatment of patients with rheumatoid arthritis (RA).
METHODS: RA synovial fibroblast-like cells were cultured with tumor necrosis factor-alpha (TNF-alpha, 10 ng/ml) in the presence or absence of T-614. After incubation, cytokine production was measured by ELISA. Expression of interleukin 6 (IL-6) and IL-8 mRNA was examined by real-time quantitative reverse transcriptase-polymerase chain reaction analysis and TNF-alpha induced nuclear factor-kappaB (NF-kappaB) activation was observed using immunostaining with an antibody against NF-kappaB p65.
RESULTS: T-614 suppressed TNF-alpha induced production of IL-6, IL-8, and monocyte chemoattractant protein 1, and also reduced the accumulation of IL-6 and IL-8 mRNA in a concentration dependent manner. T-614 interfered with the TNF-alpha induced translocation of NF-kappaB to the nucleus from the cytoplasm.
CONCLUSION: Inhibition of NF-kappaB activation and transcription of proinflammatory cytokines by T-614 contributes to its clinical antirheumatic effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11764202

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  24 in total

1.  Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain.

Authors:  K Morimoto; A Miura; Keiichi Tanaka
Journal:  Inflamm Res       Date:  2017-06-13       Impact factor: 4.575

2.  Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Sajan Shrestha; Jing Zhao; Changqing Yang; Jinping Zhang
Journal:  Clin Rheumatol       Date:  2020-02-20       Impact factor: 2.980

3.  Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro.

Authors:  Akira Miyama; Kosuke Ebina; Makoto Hirao; Gensuke Okamura; Yuki Etani; Kenji Takami; Atsushi Goshima; Taihei Miura; Shohei Oyama; Takashi Kanamoto; Hideki Yoshikawa; Ken Nakata
Journal:  J Bone Miner Metab       Date:  2021-02-09       Impact factor: 2.626

4.  Isoquinoline alkaloids from Zanthoxylum simulans and their biological evaluation.

Authors:  Sheng-Hui Yang; Yan-Qun Liu; Jun-Feng Wang; Yue-Hu Wang; Wei-Wei Pan; Wen-Bing Sheng; Rui Cai; Xiao-Jiang Zhou
Journal:  J Antibiot (Tokyo)       Date:  2014-10-01       Impact factor: 2.649

5.  A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.

Authors:  Feng Xiao; Feng Zhang; Ling-Ling Zhang; Wei Wei
Journal:  Eur J Clin Pharmacol       Date:  2017-10-19       Impact factor: 2.953

6.  Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential.

Authors:  Joshua Bloom; Christine Metz; Saisha Nalawade; Julian Casabar; Kai Fan Cheng; Mingzhu He; Barbara Sherry; Thomas Coleman; Thomas Forsthuber; Yousef Al-Abed
Journal:  J Biol Chem       Date:  2016-10-28       Impact factor: 5.157

7.  Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.

Authors:  Satoshi Mizutani; Hitoshi Kodera; Yoshiko Sato; Toshihiro Nanki; Shunji Yoshida; Hidekata Yasuoka
Journal:  Clin Rheumatol       Date:  2020-06-06       Impact factor: 2.980

Review 8.  Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis.

Authors:  Suling Liu; Yang Cui; Xiao Zhang
Journal:  Clin Rheumatol       Date:  2020-06-06       Impact factor: 2.980

9.  Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Sajan Shrestha; Jing Zhao; Changqing Yang; Jinping Zhang
Journal:  Clin Rheumatol       Date:  2021-04-29       Impact factor: 2.980

10.  Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner.

Authors:  Yue Sun; Da-Wei Ye; Peng Zhang; Ying-Xing Wu; Bang-Yan Wang; Guang Peng; Shi-Ying Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.